A digital platform for personalized medicine for immuno-oncology and inflammatory dysfunctions.
Our platform serves all stakeholders wanting to use complementary diagnostics for improving patient outcomes.
The platform addresses the scarcity of predictive and prognostic biomarkers, using strong clinical rationale, machine learning and statistical methods.
CEO
Ph.D. Cancer Research UK, Cambridge. 15 years of experience in research, translational & fundamental. Development of R&D for pharma & AI clients.
Cofounding ML engineer
Masters machine learning, CentraleSupélec. 3+ years work experience in high-impact startups. Focus on machine learning applied to oncology.
Combining multiple sources of data allows us to explore biomarkers from combinations of modalities which would be impossible to explore by a human being.
Learn moreUsing latest advances in the field of computer vision, deep learning, and machine learning, we perform a multimodal data analysis with various endpoints.
Learn moreOur models allow us to better divide patients into groups, so as to better target patients who will receive a specific treatment. This leads to better patient outcomes for both predicted responders and non-responders.
Learn moreDetecting biomarkers of response to immunotherapies and other cancer therapies to give the right therapy to the right patient, improving patient outcome. Blazar's approach is to generate complementary diagnostics that are going to speed up and give accuracy to clinical decisions but also contribute to the discovery of new digital biomarkers with clinical and industrial partners.
Platform to help pathologists report on cancer types and analyze histopathology whole slide images with productivity tools (automatic segmentation of regions of interest, report generation, assisting in the annotations, …).
SILICON REPUBLIC
10 women-led health-tech start-ups set to take Paris by stormSILICON REPUBLIC
10 women-led health-tech start-ups set to take Paris by storm